About this trial
The aim of the study is to characterize the neuroinflammatory effects of subthalamic deep brain stimulation in patients with Parkinson's disease, by analyzing changes in blood neuroinflammatory and neurodegenerative biomarkers before and after surgery (at 6 and 12 months, respectively), and comparing the changes in blood biomarkers levels with a control group of patients with advanced PD on best medical treatment.
Eligibility criteria
Qualifiers
clinically established diagnosis of PD according to the criteria of the Movement Disorder Society (MDS) (Postuma et al., Mov Disord 2015);
a minimum disease duration of 4 years;
eligibility for STN-DBS surgery according to Core Assessment Program for Surgical Interventional Therapies in PD (Defer et al., Mov Disord 1999);
age between 18 and 75 years.
Disqualifiers
inability to express an informed consent;
moderate or severe cognitive impairment (score < 24 on the Mini-Mental State Examination);
severe psychiatric symptoms (e.g., psychosis, major depression);
previous neurosurgical interventions for PD;
Trial design
Treatments tested in this trial
- Deep brain stimulation surgery
Treatment groups
Locations
Sponsors and collaborators
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lead sponsor
Ministry of Health, Italy
Collaborator
Azienda Ospedaliero-Universitaria di Modena
Collaborator
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Collaborator